Alzheimer’s disease matters because it affects an enormous and rapidly growing number of people, carries a staggering economic cost, and remains one of the few leading causes of death with no cure. Around 57 million people worldwide were living with dementia as of 2019, with Alzheimer’s being the most common form, and that number is projected to reach 153 million by 2050. It is the seventh leading cause of death in the United States, and unlike heart disease or cancer, the trajectory is still sharply climbing.
The Scale of the Problem
More than 6.5 million Americans currently live with Alzheimer’s, and the global picture is far larger. The disease slowly destroys memory, thinking skills, and eventually the ability to carry out basic tasks like eating, dressing, or recognizing family members. It is irreversible and progressive, meaning every person diagnosed will get worse over time.
The five-year mortality rate for people with Alzheimer’s is roughly 35%, and their death rate is approximately double that of people the same age without the disease. But the numbers only tell part of the story. Alzheimer’s doesn’t just shorten life. It erodes the quality of every remaining year, both for the person diagnosed and for everyone around them. People with Alzheimer’s are more likely to develop cardiovascular disease, diabetes, and stroke. Hip fractures are significantly more common. As the disease advances, complications like infections from difficulty swallowing become life-threatening.
A Massive Toll on Families
Alzheimer’s is unusual among major diseases because so much of the care falls on unpaid family members. Over 53 million Americans serve as unpaid caregivers for people who are older or have chronic conditions, and dementia care is among the most demanding forms. The economic value of that free labor is estimated at nearly $470 billion per year, a figure that has grown as the number of caregivers rose from 43.5 million in 2015 to about 53 million by 2020.
Caregiving for someone with Alzheimer’s is different from most other caregiving. It often lasts years, intensifies as the disease progresses, and involves managing behavioral changes, safety risks like wandering, and the emotional weight of watching a loved one lose their identity. Caregivers themselves face higher rates of depression, chronic stress, and physical health problems. The disease, in effect, claims more than one life at a time.
The Healthcare System Isn’t Ready
Even as the number of people with Alzheimer’s rises, the healthcare workforce is falling short. Between 34% and 59% of Americans aged 65 and older live in areas without enough dementia specialists. In a national analysis of hospital referral regions, 58% had fewer than 33 dementia specialists per 100,000 older adults, and 76% fell below the higher threshold of 45 specialists per 100,000. That gap will only widen as the population ages and the number of diagnoses increases.
This shortage means many people with Alzheimer’s are diagnosed late, managed by primary care doctors with limited dementia training, or never formally diagnosed at all. The World Health Organization has set a goal that by 2025, at least half of the estimated number of people with dementia should be diagnosed in at least 50% of countries. Currently, most countries fall well short of that target.
New Tools Are Changing Detection
For decades, confirming Alzheimer’s required expensive brain imaging or invasive spinal fluid tests. That changed with the clearance of the first blood test for diagnosing Alzheimer’s. The test measures a specific protein ratio in the blood and, in clinical studies, correctly identified 91.7% of people who had amyloid plaques confirmed by brain scan. Among people who tested negative, 97.3% truly did not have plaques. A simple blood draw that can reliably detect the disease opens the door to earlier diagnosis in ordinary doctor’s offices, not just specialized memory clinics.
Early detection matters more now than it used to, because for the first time, there are treatments that target the underlying biology. The FDA has approved therapies that work by clearing amyloid plaques, the protein clumps that build up in the brains of people with Alzheimer’s. These are not cures, and they work best in the early stages, which makes timely diagnosis critical. A blood test that catches the disease before significant damage accumulates could be the difference between qualifying for treatment and missing the window.
The Research Investment
The U.S. government now spends nearly $3.9 billion per year on Alzheimer’s and related dementia research through the National Institutes of Health, with a proposed budget of $3.98 billion for fiscal year 2026. That level of funding reflects a dramatic increase over the past decade and signals how seriously policymakers view the threat. The WHO’s global action plan calls for a doubling of worldwide dementia research, along with targets for risk reduction, public awareness campaigns, and support systems for caregivers.
Research funding at this scale is reserved for problems that threaten to overwhelm health systems. And Alzheimer’s qualifies. The combination of a growing elderly population, no way to prevent or cure the disease, and a care model that depends heavily on unpaid family labor creates a public health challenge unlike almost any other. Every year the problem is not solved, the cost and human suffering compound.
Modifiable Risk Factors Offer Some Hope
One reason Alzheimer’s draws so much public health attention is that a meaningful portion of dementia risk is tied to factors people can influence. The WHO’s action plan includes targets for reducing modifiable risk factors, with an overarching goal of a 25% relative reduction in premature mortality from dementia by 2025. The risk factors that matter most include physical inactivity, smoking, excessive alcohol use, poorly managed high blood pressure, diabetes, hearing loss, social isolation, and depression.
None of these guarantee prevention, but they shift the odds. Population-level improvements in cardiovascular health, education, and hearing care could delay or reduce millions of dementia cases worldwide. That makes Alzheimer’s not just a medical problem but a public health opportunity, one where broad lifestyle and policy changes could bend the curve even before a cure exists.